Tobin Schilke Biography and Net Worth

Chief Financial Officer of Crinetics Pharmaceuticals

Tobin “Toby” Schilke joined Crinetics as Chief Financial Officer in February 2025. Toby is a seasoned biopharma executive with more than 25 years of global pharmaceutical experience. In previous roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations.

Prior to Crinetics, Toby served as Chief Financial Officer at Revance Therapeutics, where he oversaw finance, investor relations, IT, and technical operations for a public company with 650 employees, supporting the transformation to a commercial company with two product launches and over $700 million in cumulative revenue. Previously, Toby served as Chief Financial Officer at Achaogen, where he built out the financial planning and analysis, accounting, procurement, information technology, and facilities management functions. Earlier in his career, he spent more than a decade in increasing roles of responsibility at Roche and Genentech in corporate development, commercial finance, marketing, and global operations.

Toby holds a bachelor’s degree in chemical engineering from Lafayette College, a master’s degree in chemical engineering from the University of California, Berkeley, and a master’s degree in business administration from Cornell University.

What is Tobin Schilke's net worth?: The estimated net worth of Tobin Schilke is at least $3.04 million as of March 3rd, 2026. Mr. Schilke owns 78,121 shares of Crinetics Pharmaceuticals stock worth more than $3,038,907 as of March 5th. This net worth estimate does not reflect any other investments that Mr. Schilke may own. Learn More about Tobin Schilke's net worth.
How do I contact Tobin Schilke?: The corporate mailing address for Mr. Schilke and other Crinetics Pharmaceuticals executives is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. Crinetics Pharmaceuticals can also be reached via phone at (858) 450-6464 and via email at [email protected]. Learn More on Tobin Schilke's contact information.
Has Tobin Schilke been buying or selling shares of Crinetics Pharmaceuticals?: Over the course of the past ninety days, Tobin Schilke has sold $266,304.71 in shares of Crinetics Pharmaceuticals stock. Most recently, Tobin Schilke sold 6,713 shares of the business's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $39.67, for a transaction totalling $266,304.71. Following the completion of the sale, the chief financial officer now directly owns 78,121 shares of the company's stock, valued at $3,099,060.07. Learn More on Tobin Schilke's trading history.
Who are Crinetics Pharmaceuticals' active insiders?: Crinetics Pharmaceuticals' insider roster includes Stephen Betz (Insider), Matthew Fust (Director), James Hassard (Chief Commercial Officer), Jeff Knight (COO), Alan Krasner (Chief Endocrinologist), Ajay Madan (Insider), Stephanie Okey (Director), Dana Pizzuti (Chief Medical and Development Officer), Tobin Schilke (Chief Financial Officer), Richard Struthers (CEO), Coelho Vivaldi (Director), and Marc Wilson (CFO). Learn More on Crinetics Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Crinetics Pharmaceuticals?: During the last year, insiders at the sold shares 13 times. They sold a total of 203,203 shares worth more than $7,009,291.36. The most recent insider tranaction occured on March, 3rd when Director Stephanie Okey sold 3,000 shares worth more than $119,010.00. Insiders at Crinetics Pharmaceuticals own 4.6% of the company. Learn More about insider trades at Crinetics Pharmaceuticals.
Information on this page was last updated on 3/3/2026.

Tobin Schilke Insider Trading History at Crinetics Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/3/2026	Sell	6,713	$39.67	$266,304.71	78,121

Tobin Schilke Buying and Selling Activity at Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Company Overview

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $38.90

$38.31

$39.59

50 Day Range

MA: $48.31

$39.51

$56.43

2 Week Range

Now: $38.90

$24.10

$57.99

Volume

1,079,759 shs

Average Volume

1,283,727 shs

Market Capitalization

$4.07 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23